March/April 2016

This pilot study analyzes the cost savings of utilizing a prescription medical food, serum-derived bovine immunoglobulin/protein isolate, for the management of inflammatory bowel disease in a small cohort.

In a retrospective analysis of the Optum database, overactive bladder patients treated with mirabegron bladder patients persisted longer with treatment than patients treated with tolterodine, and had reduced resource utilization and costs.

This study examined the impact of a pregabalin step therapy policy on utilization and medical costs in Humana’s Medicare and commercial plans.

This study evaluates the impact of primary and secondary nonadherence to cholesterol medication on low-density lipoprotein levels, emergency department visits, and hospitalizations.

Antimicrobial stewardship programs have been around for some time. However, a tipping point has yet to be achieved where most hospitals and long-term care facilities have effective programs.

Pain medication misuse in no longer just a medical issue alone, as payers need to consider their role and the actions they can take to address this problem.

Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.